Immunological Mechanisms and Natalizumab Treatment in Multiple Sclerosis

associated with one-year natalizumab treatment in 31 MS patients regarding cytokine and chemokine levels in CSF and blood using multiplex bead assay analyses (paper I),

Aims: The aims of this thesis were to evaluate rituximab as a treatment alternative in relapsing remitting MS (RRMS) by describing the clinical effect and patient

Aims: The aims of this thesis were to evaluate rituximab as a treatment alternative in relapsing remitting MS (RRMS) by describing the clinical effect and patient related

Department of Clinical and Experimental Medicine Faculty of Health Sciences, Linköping University,. SE-581 85 Linköping,

This process in- cludes innate immune system (macrophages, microglia, natural killer cells) and adaptive immune system (B- and T lymphocytes). Thus, both humoral..

In study II, relapsing-remitting MS patients had higher levels of neurofilament light (NFL), CXCL13, chitinase-3-like-1 (CHI3L1), and chitotriosidase 1 (CHIT1) than controls.

To validate that the definition of the pleiotropic module, derived from gene expression data, was not responsible for the enrichment, we investigated the distribution of GWAS

This fraction is used to measure whole brain atrophy in MS, and is calculated by adding grey and white matter volumes and dividing the result with the whole intra-cranial